newsfilter
← Latest News
GlobeNewswire·

Levi & Korskinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed

NEW YORK, March 05, 2026 (GLOBE NEWSWIRE) -- Grail, Inc. (NASDAQ:GRAL) lost approximately 50% of its market value after disclosing that the NHS Galleri randomized trial failed to meet its primary endpoint. Shareholders